Please complete the tables below as far as possible to enable a straightforward comparison with the existing data in the report to be made. Data for Hulin is provided as an example.

Overall Survival

	Median follow-up	Treatment arms		
Hulin et al.[58] IFM 01/01		MPT (n=113)	MP + placebo (n=116)	HR and *p*-value
Overall Survival, Median (95% CI)	47.5 months	44.0 months (33.4 to 58.7)	29.1 months (26.4 to 34.9)	HR 0.68 (95% CI not reported) p=0.028
Deaths		58/113 (51%)	76/116 (65.5%)	p=0.03
MMIX		CTDa (n=342)	MP (n=344)	HR and *p*-value
Weighted overall Survival, months Median (95% CI)	■■■■	■■■■	■■■■	■■■■
Deaths (not weighted)		■■■■	■■■■	■■■
Deaths (weighted)		■■■■	■■■■	■■■

Progression-free survival

Study	Median follow-up	Treatment arms		
Hulin et al.[58] IFM 01/01		MPT (n=113)	MP + placebo (n=116)	HR and *p*-value
Progression-free Survival, Median (95% CI)	47.5 months	24.1 (19.4 to 29.0) months	18.5 (14.6 to 21.3) months	HR 0.62, p=0.001
MMIX		CTDa (n=342)	MP (n=344)	HR and *p*-value
Weighted Progression-free survival, Median (95% CI)	■■■	■■■	■■■	■■■

Response to treatment

Study	Treatment arms		
Hulin et al.[58] IFM 01/01	**MPT (n=115)**	**MP + placebo (n=117)**	***p*-value**
Complete response at 12 months	7/107 (7%)	1/112 (1%)	p<0.001
MMIX	**CTDa (n=342)**	**MP (n=344)**	***p*-value**
Complete response (not weighted)	███████	███████	███████
Complete response (weighted)	███████	███████	███████